All In Biotech

Drug Trial Radar · NCT07917143

A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide Versus Placebo in Children and Adolescents With Hypochondroplasia

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Once-weekly Navepegritide Versus Placebo in Children and Adolescents With Hypochondroplasia

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

81

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Oct 2028

Study completion Oct 2029

Sponsor

Lead sponsor
Ascendis Pharma A/SIndustry
Sponsor type
Industry
First posted
Nov 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is being conducted to evaluate the efficacy, safety and tolerability of treatment with navepegritide subcutaneous (SC) injections once weekly in children and adolescents with hypochondroplasia aged 2 to 17 years.

Conditions

  • Hypochondroplasia

Interventions

  • NavepegritideDrug

    Administered weekly as s.c. injection. Treatment duration of up to 104 weeks

  • Placebo for NavepegritideDrug

    Administered weekly as s.c. injection. Treatment duration of up to 52 weeks of placebo for navepegritide followed by 52 weeks of navepegritide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual Growth Velocity (AGV)Time frame: Week 52

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.